C

City Therapeutics

Develops RNAi therapeutics using trigger molecules

Vice President Quality Assurance

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • A bachelor's degree in life sciences, pharmacy, chemistry, or a related field is required; an advanced degree (MS, PhD, or PharmD) is strongly preferred.
  • At least 15 years of progressive Quality Assurance experience in the biopharmaceutical or pharmaceutical industry, including a minimum of 5 years in a senior or executive leadership role.
  • Demonstrated experience building and scaling QA functions in a clinical-stage or growth-phase biopharmaceutical company.
  • Working knowledge of international regulatory frameworks, including EMA, ICH, and PMDA requirements.
  • Proven track record leading successful regulatory inspections (FDA, EMA, or equivalent) and managing health authority interactions and responses.
  • Extensive experience managing CMO, CDMO, and CRO quality relationships and overseeing multi-site QA systems.
  • Comprehensive, hands-on expertise in GMP and GCP regulations, including FDA 21 CFR Parts 210/211/312/600 and ICH Q7, Q9, Q10, and E6(R2).

Responsibilities

  • Define and lead the enterprise-wide Quality Assurance strategy, ensuring alignment with regulatory requirements, industry best practices, and business objectives.
  • Lead quality risk management activities, identify potential risks, and implement mitigation strategies proactively.
  • Build, develop, and retain a high-performing QA team, establishing clear roles, accountability structures, and career development pathways.
  • Champion and embed a proactive quality culture across all departments, serving as the organizational authority on quality matters.
  • Establish and monitor quality KPIs, metrics, and dashboards; report quality status and trends to executive leadership and the Board as appropriate.
  • Provide executive oversight of all cGXP activities, ensuring compliance with FDA, EMA, ICH, and other applicable international regulations (21 CFR Parts 210/211/312/600, ICH Q7, Q9, Q10, E6, and related guidelines).
  • Own and continuously improve the Quality Management System, including SOPs, change control, deviation and CAPA management, document control, and training programs.
  • Drive and maintain continuous inspection readiness across all sites and functions.
  • Collaborate with Regulatory Affairs to prepare and review quality sections of IND, BLA, NDA, and other regulatory submissions.
  • Serve as the primary QA lead during FDA, EMA, and other regulatory agency inspections and audits; manage all aspects of inspection response and commitments.
  • Establish and maintain a vendor qualification and audit program for all CDMOs, CMOs, CROs, and critical suppliers.
  • Negotiate, review, and execute Quality Technical Agreements with all external partners.
  • Partner with Clinical Operations, Regulatory Affairs, CMC, R&D, and Supply Chain to integrate quality requirements into every stage of the product lifecycle.
  • Support due diligence activities and integration planning for partnerships, in-licensing, and M&A transactions as needed.

Desired Qualifications

  • Experience across multiple modalities, including biologics and/or cell and gene therapies.
  • Prior experience supporting a product through BLA/NDA approval and commercial launch.

About the Company

City Therapeutics

Develops RNAi therapeutics using trigger molecules

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at City Therapeutics

See more jobs